NewMed Energy - Limited Partnership
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DKDRF research report →
Price Chart
About the company
NewMed Energy - Limited Partnership, headquartered in Herzliya, Israel, is an energy company primarily involved in the upstream oil and gas sector. Its operations encompass the exploration, development, extraction, and marketing of crude oil, natural gas, and condensate across Israel and Cyprus. The partnership possesses significant interests in several key energy projects.
- CEO
- Yossi Abu
- IPO
- 2013
- Employees
- 24
- HQ
- Herzliya, TA, IL
Get TickerSpark's AI analysis on DKDRF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.78B
- P/E
- 26.00
- Fwd P/E
- 11.97
- PEG
- -0.58
- P/S
- 7.29
- P/B
- 3.81
- EV/EBITDA
- 11.15
- Div Yield
- 3.76%
- Gross Margin
- 50.11%
- Op Margin
- 44.83%
- Net Margin
- 28.80%
- ROE
- 14.02%
- ROIC
- 7.33%
Latest fiscal year · YoY change
- Revenue
- $938.07M-17.4%
- Gross Profit
- $585.08M-18.5%
- Op Income
- $566.02M
- Net Income
- $371.29M-29.2%
- EPS
- $0.32-28.9%
- OCF Growth
- -5.3%
- FCF Growth
- -34.2%
- 52W High
- $7.32
- 52W Low
- $4.68
- 50D MA
- $5.41
- 200D MA
- $5.85
- Beta
- 0.43
- RSI (14)
- 64
- Avg Volume
- 406
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
NewMed Energy reported a strong Q2 2026 on higher production and prices, with earnings up year over year and management pointing to continued progress on Leviathan expansion and Aphrodite.· August 13, 2026
- Q2 revenue rose to about $293 million, net profit was about $117 million, and production reached about 2.7 Bcm versus roughly 2 Bcm a year earlier.
- Higher gas production and a higher average gas price drove most of the year-over-year improvement, partly offset by higher operating/depreciation costs and finance expenses.
- The company completed the third pipeline from the field to the platform and said peak annual production capacity reached 15.8 Bcm, above the initial 14.5 Bcm plan.
- Leviathan expansion Phase 1b remains on track for the second half of 2029, with the drilling rig expected toward year-end and three new production wells planned.
- Management also highlighted progress at Aphrodite, completed INGL looping work in July, and announced a $60 million dividend for the quarter.
NewMed Energy reported Q2 2026 revenue of about $293 million, net profit of about $117 million, and production of about 2.7 Bcm, versus Q2 2025 revenue of $191 million, net profit of $81 million, and production of around 2 Bcm. Management said the average gas price was $6.5 versus $5.6 in Q2 2025. Net revenues increased by $86 million year over year, including $59 million from higher production, $25 million from a higher average gas price per MMBtu, and $2.1 million from higher condensate sales, partly offset by $21 million of higher costs and expenses and $26 million of higher net finance expenses. Liquidity commentary included total net debt of approximately $1.4 billion and $550 million of available credit facilities from Israeli banks; the company also said it has bought back about $95 million under its bond buyback program. For forward outlook, management said gas prices should remain high in the next few months because Brent-linked pricing lags by about three months, Leviathan expansion Phase 1b is expected in the second half of 2029, and the FAJR+ compression project is expected toward year-end with the Nitzana pipeline ahead of Leviathan Phase 2.
The CEO’s message was that the quarter showed strong operating momentum, with higher production, strong pricing, and infrastructure projects moving ahead. He emphasized that the third pipeline and Ashdod-Ashkelon looping improve delivery capacity, and said the company is on track with Leviathan expansion and seeing good momentum at Aphrodite. His tone was upbeat and confident, especially around new capacity, project execution, and the upcoming seismic surveys at Zone I and Leviathan.
The CFO focused on the year-over-year bridge: revenue and profit improved because of higher gas volumes and prices, while higher operating costs, depreciation, and finance expenses reduced some of the upside. He cited $86 million of net revenue growth, $21 million of higher costs and expenses, and $26 million of higher net finance expenses tied mainly to the revaluation of Karish and Tanin royalties. He also noted $6.8 million of other revenues from a settlement related to the Iran license and $7.7 million of income from discontinued operations related to Tamar, plus total net debt of about $1.4 billion, $550 million of available bank credit, and about $95 million repurchased under the bond buyback program.
Analysts asked what milestones remain for an Aphrodite FID, and management said the key items are the commercial agreements, host-government agreements, midstream infrastructure, and completion of Chevron’s front-end engineering work. They also asked whether regional tensions could affect Leviathan expansion timing; management said Chevron is moving ahead with no hurdles or delays, long-lead items are ordered, and the drilling rig is expected on time or slightly early.
The bullish case is that NewMed is translating strong pricing and volume into higher earnings while still growing capacity. Management sounded confident that Leviathan expansion, Aphrodite, and new seismic work could add more value, and the newly completed infrastructure should support more deliveries to export markets.
The main risks are execution and timing: Aphrodite still needs several agreements and engineering milestones before FID, and Leviathan expansion is not expected until the second half of 2029. The company also carries about $1.4 billion of net debt, and finance expenses rose in the quarter, showing that valuation and funding issues remain relevant even with strong operating results.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 44.8%
- Shares Outstanding
- 1.17B
- Float Shares
- 525.89M
Our DKDRF coverage
Recent articles, reports, and earnings notes.
No research on DKDRF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DKDRF report →NewMed Energy - Limited Partnership (DKDRF) Q2 2026 Earnings Call Transcript
seekingalpha.com · Aug 13
NewMed Energy - Limited Partnership (DKDRF) Q4 2025 Earnings Call Transcript
seekingalpha.com · Mar 16
NewMed Energy Q1: Buy Rating As Revenue Grew
seekingalpha.com · Jun 7
Why Investors Should Consider NewMed Energy (Rating Upgrade)
seekingalpha.com · Nov 15
High Yield Oil And Gas Ranked By Relative Quality
seekingalpha.com · Nov 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.